Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

about

Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses.

P2860

Q38799856-E303C3E4-CB3F-4346-A345-491C4CCF8FD2

P2860

Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

Item

http://www.wikidata.org/entity/Q35974403

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@ast

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@en

type

Item

label

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@ast

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@en

prefLabel

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@ast

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@en

P1476

Safety and Immunogenicity of C ...... ver-Blind, Dose-Ranging Study.

@en

P2093

Casey Johnson

http://www.w3.org/2001/XMLSchema#string

Matthew Hohenboken

http://www.w3.org/2001/XMLSchema#string

Niranjan Kanesa-Thasan

http://www.w3.org/2001/XMLSchema#string

Peter Jaehnig

http://www.w3.org/2001/XMLSchema#string

Terry Poling

http://www.w3.org/2001/XMLSchema#string

P2860

Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses

Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature

Multiple contributory factors to the age distribution of disease cases: a modeling study in the context of influenza A(H3N2v)

Confronting the avian influenza threat: vaccine development for a potential pandemic.

Outbreak of variant influenza A(H3N2) virus in the United States.

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study.

Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009.

P304

72-80

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIU826

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

212

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25538277

http://www.w3.org/2001/XMLSchema#string

P932

4542591

http://www.w3.org/2001/XMLSchema#string

Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

about

P2860

P2860

Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932